Aim. To study the prescribed drug therapy, as well as adherence to it in patients with acute coronary syndrome (ACS) in real clinical practice within a year after the index event. Material and methods. The study included 327 patients who were in hospital treatment with ACS: 199 patients (60.9%) with unstable angina (UA) and 128 (39.1%) – with acute myocardial infarction (AMI). The prescribed treatment and adherence to therapy were evaluated within 12 months after the coronary event. Therapy prescribed to patients was compared with current clinical guidelines for the treatment of patients with ACS. Results. 67% of patients completed the clinical study Adherence to prescribed medication within 12 months after ACS was maximal for ACE inhibitors/angiotensin receptor blockers (83.6%), dual antiplatelet therapy (79.9%) and β-blockers (78.1%), and minimal for lipid-lowering drugs (statins; 61.6%). A significant decrease in adherence was revealed in 6 and 12 months from the initiation of therapy. Significantly higher level of adherence to DAT was found in patients with AMI compared with patients with UA (p<0.05). When analyzing the frequency of occurrence of endpoints, it was found that patients who did not adhere to treatment significantly more often had hospitalizations due to UA (15.1% vs 7.4%; p<0.05), AMI (16.9% vs 8.1%; p<0.05), death from cardiovascular causes (13% vs 10.4%; p<0.05). Conclusion. Therapy prescribed at the outpatient stage in patients with ACS in the Rostov Region corresponds to the modern clinical recommendations. Six months after hospital discharge adherence to drug therapy in patients is reduced, which requires more careful outpatient monitoring during this period. In patients who are not adherent to treatment, cardiovascular complications are significantly more frequent.
Association between the rates of poor outcomes in the patient cohort with acute coronary syndrome and polymorphisms G(−174)C in the IL6 gene and G(−1082)A in the IL10gene were determined. In total,...
Associations of polymorphisms of genes FGB G(−455)A and PROC C(−1654)Twith the frequency of poor outcomes in patients with the history of acute coronary syndrome (ACS) were studied in the Russian...
The search for new antitumor and antimetastatic therapy targets is a priority task for interdisciplinary research in medical chemistry, experimental pharmacology and pathological physiology. One of the promising scopes of research in this direction is to study the possibility of modifying the polymerization process of tubulin, the main structural component of the microtubules in the cellular cytoskeleton. Various options for influencing microtubules can be used to repurpose already known and develop new antitumor drugs.